Jacobs Levy Equity Management’s ANI Pharmaceuticals ANIP Stock Holding History

Jacobs Levy Equity Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,706	Closed	-$215K	–	970
2023 Q3	$215K	Sell	3,706 -28,311	-88%	-$1.63M	﹤0.01%	918
2023 Q2	$1.72M	Sell	32,017 -3,091	-9%	-$137K	0.01%	599
2023 Q1	$1.39M	Buy	+35,108	New	+$1.48M	0.01%	637
2014 Q3	–	Sell	-7,759	Closed	-$267K	–	820
2014 Q2	$267K	Sell	7,759 -1,580	-17%	-$49.5K	﹤0.01%	731
2014 Q1	$293K	Buy	+9,339	New	+$248K	﹤0.01%	760

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jacobs Levy Equity Management's ANIP Position: Q4 2023 in Review

Jacobs Levy Equity Management sold out of ANI Pharmaceuticals (ANIP) in Q4 2023, closing a stake of 3,706 shares — an estimated $215K sold.

Jacobs Levy Equity Management first reported a position in ANIP in Q1 2014 and held it in 5 quarters. The position peaked at $1.72M in Q2 2023. 181 funds tracked by Wall St. Rank hold ANIP as of Q4 2023.

Jacobs Levy Equity Management reported no remaining ANI Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Jacobs Levy Equity Management sold 3,706 ANI Pharmaceuticals shares in Q4 2023, an estimated $215K.
Jacobs Levy Equity Management first reported a position in ANI Pharmaceuticals in Q1 2014 and held it in 5 quarters.
Jacobs Levy Equity Management's ANI Pharmaceuticals position peaked at $1.72M in Q2 2023.
181 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2023.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2023, filed 14 Feb 2024.